Datma, a leader in federated real-world data access, and Rhythm Biosciences Ltd, a developer of predictive cancer diagnostics including its geneType risk assessment portfolio, announced a new collaboration to explore how datma. FED, Datma’s federated data platform, could support and accelerate the development and commercialization of Rhythm’s genomic-integrated cancer risk prediction tools.
Health Technology Insights: OrthAlign Expands Lantern Hip Platform for Posterior THA
As genomic-integrated risk assessment tools advance, access to comprehensive real-world data becomes increasingly critical to enhance model performance, demonstrate clinical relevance, and support regulatory and commercial strategies. Accessing these datasets is often difficult due to fragmentation across healthcare systems and privacy regulations. Datma. FED allows secure, federated access to de-identified patient data from multiple healthcare organizations without requiring centralized storage or data transfer, overcoming these challenges.
Health Technology Insights: Solventum Wins Diamond HIRC Badge for Top Supply Chain Strength
Through the collaboration, Datma and Rhythm Biosciences will evaluate how longitudinal real-world clinical data available via datma.FED can inform and improve Rhythm’s genomic-integrated risk scoring technologies. Rhythm plans to leverage these datasets to support clinical utility studies, health economic analyses, and engagement with healthcare systems to advance adoption of population-based cancer risk stratification tools.
Noah Nasser, Chief Executive Officer at Datma, stated, “We are excited to partner with Rhythm Biosciences as they expand genomic-integrated risk prediction for cancer diagnostics. Datma.FED was designed to provide secure access to high-value real-world data across multiple institutions, and this collaboration demonstrates how federated data can accelerate research, development, and real-world evidence generation in diagnostics and therapeutics.”
Dr Erika Spaeth, Director of Clinical Affairs at Rhythm Biosciences, added, “Access to reliable real-world data is essential to show the clinical value of genomic-integrated risk prediction tools. This collaboration allows us to explore federated data access to strengthen evidence generation for geneType as we progress our portfolio and engage with healthcare systems. By validating geneType within federated datasets, we aim to support population-stratified cancer screening and inform future clinical and economic implementation strategies.”
Health Technology Insights: Ferronova Raises $6 Million to Boost Image-Guided Cancer Surgery
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
